I-Tech seals market acceptance for Selektope

Vicore Pharma H., holds 17% of the shares in I-Tech AB.

Final sign-off of the antifouling active substance Selektope® by the European Commission coincides the first disclosure of a commercial application in Asia.

The first publicly-disclosed commercial application for a marine coating featuring Selektope will start on November 1 in Singapore, swiftly after developer I-Tech secured European Commission sign-off that the revolutionary antifouling substance can also be used by yards anywhere in Europe.

“We are delighted to receive sign-off from the EC,” said Philip Chaabane, Managing Director, I-Tech. “Now all antifouling coatings suppliers are at liberty to offer innovation by deploying Selektope, safe in the knowledge that they are fully approved in Japan, Korea, China and Europe.”

Selektope deters barnacles from settling on ship hulls by stimulating the swimming action of larvae. It is included as a 0.1% constituent of antifouling coatings - a fraction of the active substance needed to achieve comparable performance if traditional copper biocides are used.

I-Tech reached a non-exclusive commercial agreement covering the use of Selektope in 2014 with Chugoku Marine Paints (CMP). The first publicly-disclosed project will see a new copper-free product from CMP applied to the side-walls of the vessel Calypso for Swedish operator Laurin Maritime. The IMO II tanker is undergoing its first five year survey at Singapore yard Sembcorp. No special provisions are required beyond normal preparation work.

The project comes after several years of strong performance trial results, according to Mikael Laurin, Chief Executive Officer, Laurin Maritime. Selektope’s characteristics closely align with Laurin’s sustainability commitments, which extend to all aspects of shipboard operations, he said.

“We first took note of Selektope in 2010. Antifouling coatings have a major impact on fuel efficiency. Our ships operate in South East Asia and South America; port congestion can lead to vessels idling in tropical waters, bringing heavy fouling. I-Tech’s technology represents a major step in delivering an antifouling that performs the way we want, comparable to the performance achieved by antifouling coatings before the TBT ban in 2002.”

Masaya Hata, CMP General Manager (Sales), commented: “The extensive test applications we have made including Selektope have led us to plan for this coating to perform as a five-year period antifouling coating. We are convinced that our customers will save fuel using this coating; our plan is to evaluate performance on a working ship and position the new antifouling coating in the market over the coming three years.”

Contact details
Philip Chaabane, CEO, Philip.Chaabane@i-tech.se +46 (0) 73 910 37 08


About Us

Vicore Pharma develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. Vicore Pharma is based in Astra Zeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, see www.vicorepharma.com